Concurrent Session 1 - Matrix Turnover
Engineering TIMPs for OA therapy
Timeslot: Friday, April 28, 2017 - 8:45am to 9:15am
A central feature of osteoarthritis is degradation of the carriage extracellular matrix by matrix metalloproteinases and related aggrecanase ADAMTSs. Tissue Inhibitors of Metalloproteinases 3 (TIMP-3) is the endogenous inhibitor of these enzymes, and mice lacking TIMP-3 develop increased osteoarthritis with age. I will describe our recent work aimed at engineering TIMP-3 to increase its half life and thus improve its ability to protect cartilage against proteolytic degradation.